Advertisement

Participation in Sports for the Athlete with the Marfan Syndrome

  • Marla Mendelson
Chapter

Abstract

The Marfan syndrome was first described in 1896 by Dr. Antoine Marfan, a French pediatrician [1, 2]. He described a young girl who manifested the classic musculoskeletal findings. This syndrome along with its propensity for aortic dilatation has been recognized across the world as one of the causes of sudden death in high-profile athletes receiving considerable media attention [3]. The Marfan syndrome with aortic dilatation is related to a mutation in the fibrillin I gene [1, 2]. The incidence in the general population is approximately 1 in 5,000 to 1 in 10,000, and it has an autosomal dominance pattern of inheritance [4, 5]. It is a syndrome comprising cardiovascular, visual, and skeletal manifestations, which will be discussed in this chapter.

Keywords

Aortic Dissection Aortic Root Club Foot Bicuspid Aortic Valve Marfan Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Braverman, A. Exercise and the Marfan syndrome. Clinical Suppl: Cardiol. 1998:30:S387–S395.Google Scholar
  2. 2.
    Pyeritz, RE, Rimoin, DL, Conner, M, et al. Marfan syndrome and other disorders of fibrillin. In: Principles Practice of Medical Genetics. 3rd ed. New York: Churchill Livingston, 1997:1027–1066.Google Scholar
  3. 3.
    Saeed, IM, Braverman, AC. Approach to athlete with thoracic aortic disease. Curr Sports Med Rep. 2007:6:101–107.PubMedCrossRefGoogle Scholar
  4. 4.
    Kinoshita N, Milmura, J, Obayashi, C, et al. Aortic root dilatation among young competitive athletes: Echocardiographic screening of 1929 athletes between 15 and 34 years of age. Am Heart J. 2000:139:723–728.PubMedCrossRefGoogle Scholar
  5. 5.
    Maron, BJ, Ackerman, MJ, Nishimura, RA, et al. Task force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol. 2005:45:1340–1345.PubMedCrossRefGoogle Scholar
  6. 6.
    Giese, EA, O’Connor, FG, Brennan, FH, et al. The athletic preparticipation evaluation: Cardiovascular assessment. Am Fam Physician. 2007:75:1008–1014.PubMedGoogle Scholar
  7. 7.
    Keane, MG, Pyeritz, RE. Medical management of Marfan syndrome. Circulation. 2008:117:2802–2813.PubMedCrossRefGoogle Scholar
  8. 8.
    De Paepe, A, Devereux, RB, Dietz, HC, et al. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet. 1996:62:417–426.PubMedCrossRefGoogle Scholar
  9. 9.
    Seto, CK. Preparticipation cardiovascular screening. Clin Sports Med. 2003:22:23–35.PubMedCrossRefGoogle Scholar
  10. 10.
    Germain, DP. Ehlers-Danlos syndrome type IV. ORJD. 2007:2:32–41.Google Scholar
  11. 11.
    Callewaert, B, Malfait, F, Loeys, B, et al. Ehlers-Danlos syndromes and Marfan syndrome. Best Pract Res Clin Rheumatol. 2008:22:165–189.PubMedCrossRefGoogle Scholar
  12. 12.
    Lacro, RV, Dietz, HC, Wruck, LM, et al. Rationale and design of a randomized clinical trial of B-blocker therapy (Atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J. 2007:154:624–631.PubMedCrossRefGoogle Scholar
  13. 13.
    Ammash, NM, Sundt, TM, Connolly, HM. Marfan syndrome-diagnosis and management. Curr Probl Cardiol. 2008:33:7–39.PubMedCrossRefGoogle Scholar
  14. 14.
    Dean, JC. Marfan syndrome: Clinical diagnosis and management. Eur J Hum Genet. 2007:15:724–733.PubMedCrossRefGoogle Scholar
  15. 15.
    Maron, BJ, Douglas, PS, Graham, TP, et al. Task force 1: Preparticipation screening and diagnosis of cardiovascular disease in athletes. J Am Coll Cardiol. 2005:45:1322–1326.PubMedCrossRefGoogle Scholar
  16. 16.
    Figueiredo, S, Martins, E, Lima, MR, et al. Cardiovascular manifestations in Marfan syndrome. Rev Port Cardiol. 2001:20:1203–1218.PubMedGoogle Scholar
  17. 17.
    Giske, L, Stanghelle, JK, Reid-Hendrikssen, S, et al. Pulmonary function, working capacity and strength in young adults with Marfan syndrome. J Rehabil Med. 2003:35:221–228.PubMedCrossRefGoogle Scholar
  18. 18.
    Crilley, JG, Bendahan, D, Boehm, E, et al. Investigation of muscle bioenergeitics in the Marfan syndrome indicates reduced metabolic efficiency. J Cardiovasc Magn Reson. 2007:9:709–717.PubMedCrossRefGoogle Scholar
  19. 19.
    Matt, P, Habashi, J, Carrel, T, et al. Recent advances in understanding Marfan syndrome: Should we not treat surgical patients with losartan? J Thorac Cardiovasc Surg. 2008:135:389–394.PubMedCrossRefGoogle Scholar
  20. 20.
    Waseem, M, Ganti, S. Chest pain in an adolescent with Marfan syndrome. J Emerg Med. 2007:20:30–33.Google Scholar
  21. 21.
    Maron, BJ, Chaitman, BR, Ackerman, MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular disease. Circulation. 2004:109:2807–2816.PubMedCrossRefGoogle Scholar
  22. 22.
    Lawless, CE, Best, TM. Electrocardiograms in athletes: Interpretation and diagnostic accuracy. Am Coll Sports Med. 2007:40:787–798.Google Scholar
  23. 23.
    Judge, DP, Dietz, HC. Therapy of Marfan syndrome. Annu Rev Med. 2008:59:43–59.PubMedCrossRefGoogle Scholar
  24. 24.
    Patel, ND, Weiss, ES, Alejo, DE, et al. Aortic root operations for Marfan syndrome: A comparison of the Bentall and valve-sparing procedures. Ann Thorac Surg. 2008:85:2003–2011.PubMedCrossRefGoogle Scholar
  25. 25.
    Kallenbach, K, Karck, M, Pak, D, et al. Decade of aortic valve sparing reimplantation. Are we pushing the limits too far? Circulation. 2005:112:I-253–I-259.Google Scholar
  26. 26.
    Sheick-Yousif, B, Sheinfield, A, Tager, S, et al. Aortic root surgery in Marfan syndrome. Isr Med Assoc J. 2008:10:189–193.PubMedGoogle Scholar
  27. 27.
    Williams, MA, Haskell, WL, Ades, PA, et al. Resistance exercise in individuals with and without cardiovascular disease: 2007 Update. Circulation. 2007:116:572–584.PubMedCrossRefGoogle Scholar
  28. 28.
    Mitchell, JH, Haskell, W, Snell, P, et al. Task force 8: Classification of sports. J Am Coll Cardiol. 2005:45:1364–1367.PubMedCrossRefGoogle Scholar
  29. 29.
    Maron, BJ, Zipes, DP. Introduction: Eligibility recommendations for competitive athletes with cardiovascular abnormalities-General considerations. J Am Coll Cardiol. 2005:45:0735–1097.Google Scholar
  30. 30.
    Maron, BJ. Sudden death in young athletes. N Engl J Med. 2003:349:1064–1075.PubMedCrossRefGoogle Scholar
  31. 31.
    Januzzi, JL, Isselbacher, EM, Fattor, R, et al. Characterizing the young patient with aortic dissection: Results from the International Registry of Aortic Dissection (IRAD). J Am Coll Cardiol. 2004:43:665–669.PubMedCrossRefGoogle Scholar
  32. 32.
    Shores, J, Berger, KR, Murphy, EA, et al. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfans syndrome. N Engl J Med. 1994:330:1335–1341.PubMedCrossRefGoogle Scholar
  33. 33.
    Yetman, AT, Bornemerier, RA, McCindle, BW. Long-term outcome in patients with Marfan syndrome: Is aortic dissection the only cause of sudden death? J Am Coll Cardiol. 2003:41:329–332.PubMedCrossRefGoogle Scholar
  34. 34.
    Bonow, RO, Cheitlin, MD, Crawford, MH, et al. Task force 3: Valvular heart disease. J Am Coll Cardiol. 2005:45:1334–1340.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Marfan Syndrome Program, Department of CardiologyNorthwestern Feinberg School of MedicineChicagoUSA

Personalised recommendations